You have 9 free searches left this month | for more free features.

Recurrent Cervical Carcinoma

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer Trial in Boston (Durvalumab, Tremelimumab,

Terminated
  • Recurrent Gynecological Cancer
  • +10 more
  • Boston, Massachusetts
    Martin King
Oct 4, 2022

Human Papilloma Virus Circulating Tumor DNA in Cervical Cancer

Recruiting
  • Cervical Adenosquamous Carcinoma
  • +26 more
  • Biospecimen Collection
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 4, 2023

Targeted Therapy, Chemo, Recurrent Cervical Carcinoma Trial in Beijing (Donafenib combined with paclitaxel and platinum ± PD-1

Recruiting
  • Targeted Therapy
  • +6 more
  • Donafenib combined with paclitaxel and platinum ± PD-1 antibody
  • Beijing, Beijing, China
    Lei Li
Mar 26, 2022

Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma, Persistent Cervical Carcinoma Trial in Beijing (Tislelizumab plus

Recruiting
  • Recurrent Cervical Carcinoma
  • +9 more
  • Tislelizumab plus radiotherapy
  • Beijing, Beijing, China
    Lei Li
Apr 1, 2022

PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer

Recruiting
  • Immune Checkpoint Inhibitors
  • +9 more
  • Radiotherapy for targeted lesions and PD-1 antibody
  • Beijing, Beijing, China
    Lei Li
Apr 1, 2022

Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (Chemotherapy plus apatinib)

Completed
  • Recurrent Cervical Carcinoma
  • +5 more
  • Chemotherapy plus apatinib
  • Beijing, Beijing, China
    Lei Li
Mar 12, 2022

Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy Trial run by the Precigen, Inc (PRGN-2009 plus Pembrolizumab,

Not yet recruiting
  • Cervical Cancer
  • +2 more
  • PRGN-2009 plus Pembrolizumab
  • Pembrolizumab alone
  • Bethesda, Maryland
    National Institute of Health
Nov 27, 2023

Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (A combination of anti-PD-1

Completed
  • Recurrent Cervical Carcinoma
  • +4 more
  • A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel
  • Beijing, Beijing, China
    Lei Li
Mar 12, 2022

Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (Anti-PD-1 antibody camrelizumab,

Recruiting
  • Recurrent Cervical Carcinoma
  • +5 more
  • Anti-PD-1 antibody camrelizumab
  • Albumin-bound paclitaxel
  • Beijing, Beijing, China
    Lei Li
Mar 12, 2022

Ovarian Tumors, Endometrial Tumors, Uterine Cervical Tumors Trial (Dostarlimab, Bevacizumab, Doxorubicin)

Not yet recruiting
  • Ovarian Neoplasms
  • +5 more
  • (no location specified)
Sep 3, 2023

Carcinomas, Cervix Cancer, Cervical Cancer Trial in Houston (AK104)

Recruiting
  • Carcinomas
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2022

Malignant Female Reproductive System Tumor, Recurrent Cervical Carcinoma, Recurrent Endometrial Carcinoma Trial in Houston

Recruiting
  • Malignant Female Reproductive System Neoplasm
  • +24 more
  • Quality-of-Life Assessment
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 6, 2022

HPV-Related Cervical Carcinoma, HPV-Related Malignancy, Cervical Cancer Trial (VB10.16, Atezolizumab Injection [Tecentriq],

Not yet recruiting
  • HPV-Related Cervical Carcinoma
  • +2 more
  • VB10.16
  • +2 more
  • (no location specified)
Oct 24, 2023

MRI and PET Imaging in Predicting Treatment Response in Stage

Active, not recruiting
  • Cervical Adenocarcinoma
  • +12 more
  • Computed Tomography
  • +5 more
  • Miami, Florida
  • +5 more
Oct 4, 2022

Renal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer Trial in Shanghai (SHR-1210, Famitinib)

Recruiting
  • Renal Cell Carcinoma
  • +4 more
  • Shanghai, Shanghai, China
    Huadong Hospital Affiliated to Fudan University
Jun 30, 2022

Recurrent Cervical Carcinoma, Metastatic Cervical Cancer Trial in Guangzhou, Guanzhou (SHR-1210, Apatinib)

Active, not recruiting
  • Recurrent Cervical Carcinoma
  • Metastatic Cervical Cancer
  • Guangzhou, Guangdong, China
  • +2 more
Sep 24, 2021

Localized Prostate Carcinoma, Locally Advanced Cervical Carcinoma, Locally Advanced Rectal Carcinoma Trial in Duarte (procedure,

Recruiting
  • Localized Prostate Carcinoma
  • +17 more
  • Biospecimen Collection
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Feb 1, 2023

Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive, Metastatic Malignant Tumor Trial in Houston (DNA

Active, not recruiting
  • Human Papillomavirus-16 Positive
  • +20 more
  • DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457
  • Durvalumab
  • Houston, Texas
    M D Anderson Cancer Center
Feb 11, 2022

Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC) Trial in Gainesville, Jacksonville (LITT +

Recruiting
  • Melanoma
  • +14 more
  • LITT + Pembrolizumab
  • Gainesville, Florida
  • +1 more
Aug 22, 2022

Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (ONM-501, Cemiplimab)

Not yet recruiting
  • Triple Negative Breast Cancer
  • +13 more
  • (no location specified)
Aug 29, 2023

Squamous Cell Lung Cancer, Vulvar Cancer, Penile Cancer Trial in France (pembrolizumab; vorinostat)

Active, not recruiting
  • Squamous Cell Lung Cancer
  • +5 more
  • pembrolizumab; vorinostat
  • Angers, France
  • +13 more
Jan 4, 2023

Recurrent Cervical Carcinoma, Radiotherapy, Epidermal Growth Factor Receptor Trial in Beijing (Combination of nimotuzumab and

Recruiting
  • Recurrent Cervical Carcinoma
  • +6 more
  • Combination of nimotuzumab and radiotherapy
  • Beijing, Beijing, China
    Lei Li
Dec 18, 2020

Endometrioid Cancer, Mucinous Ovarian Cancer, High Grade Serous Ovarian Cancer Trial in Oklahoma City (VS-6766 + defactinib)

Not yet recruiting
  • Endometrioid Cancer
  • +3 more
  • VS-6766 + defactinib
  • Oklahoma City, Oklahoma
    Stephenson Cancer Center
Aug 19, 2022

Chemo, Anti-pd-1 Antibody, Cervical Neuroendocrine Carcinoma Trial in Beijing (Drug therapy)

Recruiting
  • Chemotherapy
  • +6 more
  • Drug therapy
  • Beijing, Beijing, China
    Lei Li
Nov 15, 2020

Cervical Cancer Trial (Nimotuzumab?Tislelizumab)

Not yet recruiting
  • Cervical Cancer
  • (no location specified)
Sep 9, 2023